| Name | Title | Contact Details |
|---|---|---|
Craig Randall |
SVP, Platform R&D | Profile |
Delrin® is a highly adaptable acetal homopolymer resin that bridges the performance gap between plastics and metals and offers unique properties. Manufacturers count on Delrin® for high load mechanical applications and precision parts, where strength, stiffness, stability, and reliability are important. Applications range from gears, safety restraint components, door system, and conveyor systems components to medical delivery devices, ski bindings, zip fasteners and many others across a wide range of products and industries
Phoenix Flavors & Fragrances is a leading developer and manufacturer of customized flavors and fragrances, with over two decades of experience in the industry. The company is dedicated to delivering high-quality, artisanal products that help clients innovate and stay competitive. Phoenix collaborates closely with its customers to create bespoke solutions, ensuring that each product meets the highest standards of quality and performance. Based in New Jersey, Phoenix employs between 501 and 1000 people and has a strong regulatory team and advanced quality assurance laboratories. This enables the company to maintain compliance with industry regulations and adapt to changing consumer preferences. In 2022, Phoenix expanded its capabilities by acquiring Innovative Fragrances, enhancing its offerings in the home fragrance, personal care, candles, and air fresheners markets. The company serves a diverse range of brands across various sectors, including food, beverages, and personal care.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
The Louis D. Brandeis Center, Inc. (LDB) is an independent, non-partisan institution for public interest advocacy, research and education. The Centers mission is to advance the civil and human rights of the Jewish people and to promote justice for all.